Skip to main content
Premium Trial:

Request an Annual Quote

Oligo Factor Opens Production Facility in Mass.

NEW YORK (GenomeWeb News) – Oligonucleotide synthesis startup Oligo Factor has opened a production facility in Holliston, Mass., the privately funded company said last week.
 
The company was founded in 2006 and specializes in "medium-scale" synthesis of DNA and RNA — on the order of tens of milligrams to multiple grams of oligos.
 
According to the company, the benefits of oligo synthesis on this scale are “predictably high quality, excellent yields, and low cost of manufacturing.”
 
Company co-founder Tim McGrath said in a statement that the company fills a niche between the “high-volume, micro-scale oligo synthesis companies” and the “the pharmaceutical-grade oligo synthesis houses.”

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.